IDO1 and colorectal carcinoma: In this study, we describe the assessment of immune (CD3, CD4, CD8, CD20 and FOXP3) and immune-checkpoint (ICOS, IDO-1 and PD-L1) biomarkers using digital image analysis in stage II–IV CRC patients (n = 1724).